Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | LSS | P48449 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12346732 | 0.95 | THRB (0.43) | THRBPOLBLMNADRD3MEN1 | |
| Trifluoroacetic Acid SCHEMBL2241541 | 0.89 | TP53 (0.42) | THRBLMNADRD3MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL2237417 | 0.89 | BDKRB1 (0.38) | MEN1KMT2ACYP3A4BDKRB1 | |
| Trifluoroacetic Acid SCHEMBL2236099 | 0.88 | BDKRB1 (0.38) | MEN1KMT2ABDKRB1 | |
| Trifluoroacetic Acid SCHEMBL2242040 | 0.88 | BDKRB1 (0.40) | LMNAMEN1KMT2ABDKRB1DRD2 | |
| Trifluoroacetic Acid SCHEMBL2237661 | 0.87 | KDM4E (0.44) | POLBLMNAMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL2243351 | 0.86 | BDKRB1 (0.39) | MEN1KMT2ABDKRB1DRD2HTR2A | |
| Trifluoroacetic Acid SCHEMBL2239467 | 0.86 | BDKRB1 (0.49) | BDKRB1HTR2A | |
| SCHEMBL2236784 | 0.86 | THRB (0.46) | THRBPOLBLMNADRD3MEN1 | |
| Trifluoroacetic Acid SCHEMBL2240559 | 0.85 | BDKRB1 (0.50) | MEN1KMT2ABDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | claimed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | claimed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | THRB 391/4885POLB 2370/4885LMNA 594/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | THRB 421/4885POLB 2675/4885LMNA 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.